Member Info for Jimzi

Client list looks blue chip for the region.

Is this related to us?

Yes, the day shares give you a money back guarantee, we'll let you know

32m. Etched on ones memory!

Equally, it appears no one can seriously be arsed to sell at this level - reached the point of why bother

To me the FDA has said to MTFB, you can't prove there is no dili as your trial size not big enough to statistically cover 1 in 10,000.
I must be wrong cause if I'm right you need 10,000 in your trial.

Someone - esp from MTFB, must be able to summarise on one page what the problem is for intelligent but non medical peeps. Lift the veil of vagueness and spell it out so the market can digest it

ah, but PF didn't do this one - Sutcliffe the port king did.
I did say he was a useful addition.

Per new link posted today.

Most of the drugs withdrawn from the market for hepatotoxicity have caused death or
transplantation at frequencies in the range of =1 per 10,000, so that a single case of such an event
rarely would be found even if several thousand subjects were studied.

So it appears your very unlikely to pick it up in P3 - any company trial.

And is 1 in 10,000 bad.

That UN report says there are now 1m deaths from AB resistance. Perspective?

I can't get my head around any of it

HL have 5m at 12p. Dunno about expiry date. Good either way

might or it might not- until the way forward is revealed none of us know. You’ve clearly made your mind up and that’s fine but it’s your opinion- I will wait for more information

Woody under FCA investigation- shouldn’t affect HVO but not great for stability

They haven’t been keen on AIM for years. Never said it wasn’t an issue. I was saying we have no idea what big pharma think about coming in at this stage. There is a world outside this bb. Interesting point on post hoc medical history review as an option.

Quite a methodical post for you.

Must admit myself, we have an African contract unliaterally signed for 6 months going nowhere and here we've started without the contract does sort of turn normal business on its head.

What you get in higher risk places I suppose.

Fair dos - but what about the % split of fee.

Tell him material revenue increase is no use to assess value at all as the norm is 5% or more of existing. At least get a very material out of him!! [also he quoted figures for Iran so be consistent}

If he wants it above nominal, he has to embellish it a bit more

If you trade according to that guff - good luck.

The sp is 3p - battered to death [made worse by AMPs forced / margin style exit] and there is zero positive sentiment. That may well be true but at this stage you have to take a macro decision - the AB warchest is near empty - the AB non resistant war chest is empty bar iclaprim - so what is the likelihood of a pharma joining to get it over the line on potentially firesale terms.

Depression for PIs could easily be matched by the rubbing of hands of several big pharmas
No idea - totally possible

Hi anyone

The LOI is with Scanport. WSG have a tech partnership with Scanport. What % of Scanports overall contract income is due to the tech partnership and is that agreement 50/50? and please don't accept its confidential!!
Thanks in advance.

It clearly means that should a large trial be necessary, they have the ability to do it - they have planned for all scenarios which is what you do if you have an unknown actionto do. .
Its not difficult to understand - whether you believe it is up to you but the addition of the new man points to them expanding their options / strategy

Yep, supply dried up - back to nominal Foxy!

Hehe - they are all disclosed under exceptional items [every year]

And you can't argue with that description.

Good but no monetary figures and still a bloody LOI

Material revenue addition could mean from 5% to anything.

Not complaining but as usual, too vague